The World Health Organization has recently labeled obesity as one of the top global health problems. One of the primary reasons for the increase in chronic kidney disease is the increase in obesity related type 2 diabetes and its co-existence with hypertension. The clustering of cardiovascular risk factors such as inflammation, endothelial dysfunction and insulin resistance are intertwined in obesity and hypertension. This triad of risk factors is largely responsible for the progression of chronic kidney disease in obesity and hypertension or what is now known as Cardiometabolic Syndrome. TNF- is an important cytokine secreted by adipose tissue that can increase cardiovascular risk and end organ damage in obesity. We have recently demonstrated that TNF- can decrease Cyp2c derived epoxyeicosatrienoic acids (EETs). These Cyp2c derived epoxyeicosanoids have renal and cardiovascular protective properties. A signaling pathway that could possible link TNF- and epoxides to endothelial dysfunction and renal damage is NFB activation of cell adhesion molecules such as MCP-1. The contribution of TNF-, epoxyeicosanoids, and NFB to the progression of chronic kidney disease in obesity and hypertension has not been elucidated. Therefore, we will test the hypothesis that increased TNF- , decreased epoxides and increased MCP-1 contribute to renal vascular injury in obesity and hypertension. We will determine the effects of high fat diet induced obesity on afferent arteriolar function, blood pressure and renal injury in hypertensive animals. The current proposal will define the contribution of TNF-, EETs, NFB and MCP-1 and interactions between these pathways in obesity and hypertension. This proposal incorporates novel metabolic oxylipid profiling, RT-PCR arrays and targeted analysis of cellular mechanisms that will allow for unique insight concerning mechanisms that contribute to the progression of kidney disease in obesity and hypertension. Collectively, the proposed experiments in this application will provide novel mechanistic insight on the progression of chronic kidney disease in obesity and hypertension. Project Narrative: The World Health Organization has recently labeled obesity as one of the top global health issues. One of the primary reasons for the increase in chronic kidney disease is the increase in obesity related diabetes and its co- existence with hypertension. This project will test the hypothesis that interactions between fatty acid metabolites and inflammatory molecules accelerate the progression of chronic kidney disease in obesity and hypertension. On the whole, the proposed experiments in this application will provide novel insight and therapeutic targets for the treatment of chronic kidney disease in obesity and hypertension.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL059699-11
Application #
7626415
Study Section
Hypertension and Microcirculation Study Section (HM)
Program Officer
Barouch, Winifred
Project Start
1998-01-01
Project End
2012-05-31
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
11
Fiscal Year
2009
Total Cost
$376,185
Indirect Cost
Name
Medical College of Wisconsin
Department
Pharmacology
Type
Schools of Medicine
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Deng, Bing-Qing; Luo, Ying; Kang, Xin et al. (2017) Epoxide metabolites of arachidonate and docosahexaenoate function conversely in acute kidney injury involved in GSK3? signaling. Proc Natl Acad Sci U S A 114:12608-12613
Hwang, Sung Hee; Wagner, Karen; Xu, Jian et al. (2017) Chemical synthesis and biological evaluation of ?-hydroxy polyunsaturated fatty acids. Bioorg Med Chem Lett 27:620-625
Liu, Jun-Yan; Morisseau, Christophe; Huang, Huazhang et al. (2016) Screening of soluble epoxide hydrolase inhibitory ingredients from traditional Chinese medicines for anti-inflammatory use. J Ethnopharmacol 194:475-482
Imig, J D (2016) Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function. Adv Pharmacol 77:105-41
Liu, Jun-Yan; Tsai, Hsing-Ju; Morisseau, Christophe et al. (2015) In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors. Biochem Pharmacol 98:718-31
Wecksler, Aaron T; Hwang, Sung Hee; Liu, Jun-Yan et al. (2015) Biological evaluation of a novel sorafenib analogue, t-CUPM. Cancer Chemother Pharmacol 75:161-71
Walkowska, A; Kuczeriszka, M; Sadowski, J et al. (2015) High salt intake increases blood pressure in normal rats: putative role of 20-HETE and no evidence on changes in renal vascular reactivity. Kidney Blood Press Res 40:323-34
Bettaieb, Ahmed; Chahed, Samah; Tabet, George et al. (2014) Effects of soluble epoxide hydrolase deficiency on acute pancreatitis in mice. PLoS One 9:e113019
Wecksler, Aaron T; Hwang, Sung Hee; Wettersten, Hiromi I et al. (2014) Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB. Anticancer Drugs 25:433-46
Kujal, Petr; ?ertíková Chábová, Vera; Škaroupková, Petra et al. (2014) Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. Clin Exp Pharmacol Physiol 41:227-37

Showing the most recent 10 out of 93 publications